Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/14/2017 07/17/2017 07/18/2017 07/19/2017 07/20/2017 Date
79.9(c) 80.15(c) 80.5(c) 81.2(c) 81.3(c) Last
3 573 880 3 795 292 6 436 615 4 007 197 5 591 907 Volume
+0.25% +0.31% +0.44% +0.87% +0.12% Change
More quotes
Financials ($)
Sales 2017 48 514 M
EBIT 2017 11 606 M
Net income 2017 7 515 M
Debt 2017 15 441 M
Yield 2017 3,35%
Sales 2018 50 200 M
EBIT 2018 12 526 M
Net income 2018 8 589 M
Debt 2018 13 286 M
Yield 2018 3,52%
P/E ratio 2017 24,00
P/E ratio 2018 21,09
EV / Sales2017 4,91x
EV / Sales2018 4,70x
Capitalization 222 570 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
09/14Presentation
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
05:54p NOVARTIS : CAR-T cell therapy CTL019 unanimously 10-0 recommended for approval b..
01:01p NOVARTIS AG : Earnings Review and Free Research Report: Novartis' EPS Grew 15% o..
07/18 NOVARTIS AG (NYSE : NVS) reported earnings of $1.22 per share beating Walls Stre..
07/18 NOVARTIS : beats 2Q profit forecasts
07/18DJNOVARTIS : Shares Rise 2% After "Solid" 2Q Earnings -- Market Talk
07/18DJCORRECT : Novartis Second-Quarter Net Income $1.98 Billion, Beating Expectations
07/18DJNOVARTIS : Second-Quarter Core Net Income $2.87 Billion, Beating Expectations
07/18 NOVARTIS : Q2 results confirm full year guidance. Strong pipeline results underp..
07/14 NOVARTIS : $6.42 Million Federal Contract Awarded to Sandoz
07/14 NOVARTIS : confirms 5 year data for first and only fully-human IL-17A inhibitor ..
More news
Sector news : Pharmaceuticals - NEC
03:20p ABBOTT LABORATORIES : lifts profit forecast as it integrates St. Jude deal
07/19DJGLAXOSMITHKLINE : to Sell Its U.K. Horlicks Brand
07/19DJJOHNSON & JOHNSON : J&J Expects Drug Sales to Pick Up -- WSJ
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS 
2016A trend reversal can be anticipated
More Strategies
Latest Tweets
03:08p$EXEL: Exelixis settles its dispute w/ Genentech, Roche (RHHBY) member, conce.. 
02:50pRoche dumps Oryzon’s epigenetic AML, solid tumor drug   
02:44p#TDF2017 100km to go and the chase group with De Marchi, Moinard and Roche is..
1
02:21pRoche dumps Oryzon’s epigenetic AML, solid tumor drug:
2
02:17pNovartis, Sanofi-backed NeuroVia closes $14M series A for X-ALD work  
More tweets
Qtime:309
News from SeekingAlpha
07/19 Novartis Will Hit $100 This Year
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/19 Immunogen Finally Moving 'FORWARD'?
07/18 Investors Waiting In BioLineRx
07/18 Novartis AG 2017 Q2 - Results - Earnings Call Slides
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 85,1 $
Spread / Average Target 0,17%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS8.64%222 570
JOHNSON & JOHNSON17.36%364 233
ROCHE HOLDING LTD.4.56%220 588
PFIZER3.51%200 211
MERCK AND COMPANY6.37%171 276
SANOFI6.94%119 307